Medtronic plc has announced a strategic partnership with DASI Simulations to enhance outcomes for patients undergoing transcatheter aortic valve replacement (TAVR) in the United States. The collaboration will integrate DASI Simulations' FDA-cleared, AI-driven predictive modeling and digital twin technology into the TAVR workflow, providing clinicians with patient-specific, device-agnostic insights to support more precise and personalized treatment decisions. The partnership aims to improve operational efficiency, clinical decision-making, and overall standards of care by enabling simulation-based planning for structural heart procedures. Participating sites will receive full support from both Medtronic and DASI Simulations teams as they demonstrate the clinical and operational value of this technology-driven approach.